Biopharmaceutical stocks are taking another serious beating today. Shares of BioMarin Pharmaceutical (BMRN -1.25%) fell by as much as 10%, Bristol-Myers Squibb's (BMY -0.95%) stock dipped by 12.7%, and bluebird bio (BLUE -9.61%) lost 18.7% of its value in early-morning trading.
Fortunately, all three of these biopharma stocks have bounced off their intraday lows -- at least to a degree. Nonetheless, BioMarin's stock is still down by 6.24%, Bristol's shares are off by 3.24%, and bluebird is trading 11% lower from where it started the day, as of 12:07 p.m. EDT Monday.
These top biopharma companies are taking another step backward today in response to the rapid spread of the COVID-19 illness, which is threatening to push the world into an economic recession. The Federal Reserve took decisive action on Sunday by cutting interest rates to near zero and announcing plans to roll out a $700 billion quantitative easing program soon.
The moody market, however, is clearly unfazed by the latest fiscal-policy move, which is designed to ensure the smooth functioning of the financial system during this chaotic period. Companies like BioMarin, Bristol, and bluebird, after all, probably won't even experience a dramatic impact to their top or bottom lines from this global pandemic. This is panic selling, plain and simple.
Are any of these biopharma stocks worth buying on the heels of this panic-induced downturn? BioMarin sports a solid portfolio of rare disease medications that are currently racking up sales at breakneck pace. What's more, the company should bring two more high-value drugs to market in the near future. So, in a word, it might be a good idea to add this name to your portfolio in the wake of this largely unwarranted sell-off.
The same arguably goes for Bristol's stock. Bristol's oncology portfolio and pipeline are among the very best in the industry. Moreover, there's no reason to believe that cancer patients are going to stop receiving treatment because of the COVID-19 pandemic. Bristol may experience a modest drop-off in international sales, but not to the degree the market is forecasting via this pullback.
Bluebird may be a different story altogether. The company has been locked in a prolonged downward trend due to concerns about potential competitors in the rare blood disorder space. These fears may turn out to be unwarranted, but it's arguably a good idea to take a wait-and-see approach with this name for the moment.